00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
21:19 , May 17, 2019 |  BioCentury  |  Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
11:10 , May 8, 2019 |  BC Extra  |  Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay...
20:29 , Apr 29, 2019 |  BC Extra  |  Company News

With Immunomedics ADC deal, Everest bolsters cancer pipeline

Undeterred by a complete response letter issued by FDA in January for Immunomedics' sacituzumab govitecan, Everest obtained the therapy's rights in several Asian territories, making the antibody-drug conjugate Everest's most advanced oncology asset thus far....
13:54 , Apr 15, 2019 |  BC Extra  |  Financial News

Chi-Med planning Hong Kong listing

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) announced its intent to list on the Hong Kong stock exchange via a global offering. The company has submitted an application seeking a listing in 3Q19; terms have yet...
21:00 , Apr 12, 2019 |  BC Extra  |  Company News

J&J's Balversa gets accelerated approval for bladder cancer

FDA granted Janssen's Balversa erdafitinib accelerated approval to treat bladder cancer, making it the first FGFR kinase inhibitor to gain U.S. approval. Balversa is indicated to treat adults with locally advanced or metastatic urothelial carcinoma...
12:19 , Apr 4, 2019 |  BC Extra  |  Financial News

Liver disease play NGM raises $106.7M in IPO

Shares in NGM slipped $1.30 to $14.70 on Thursday after the company raised $106.7 million in an IPO that priced at the top of the company's proposed range. NGM Biopharmaceuticals Inc. (NASDAQ:NGM) sold 6.7 million...
18:48 , Mar 26, 2019 |  BC Extra  |  Financial News

NGM could get $975M valuation in NASDAQ IPO

After setting its NASDAQ IPO terms on Monday, NGM would be valued at $975 million if it prices the offering at the midpoint of its proposed range. The valuation includes a concurrent private placement of...
17:23 , Mar 22, 2019 |  BC Week In Review  |  Company News

Merck extends discovery partnership with NGM, drops obesity candidate

Merck & Co. said it will extend by two years its research collaboration with NGM and provide an additional $20 million in R&D funding. The pair initially partnered for five years in 2015 to discover...
23:01 , Mar 21, 2019 |  BC Extra  |  Financial News

Qiming backs Abbisko in $42M series B

Abbisko raised a $42 million series B round led by new investor Qiming Venture Partners to advance its oncology compounds into the clinic and further expand its discovery pipeline. Abbisko Therapeutics Co. Ltd. (Shanghai, China)...